Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID DTD0246 Transporter Info
Gene Name SLC28A3
Transporter Name Concentrative Na(+)-nucleoside cotransporter 3
Gene ID
64078
UniProt ID
Q9HAS3
Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)

Approved Drug

  Adenosine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Adenosine inhibits the transportation of Uridine by SLC28A3 [1]

Affected Drug/Substrate

 Uridine Modulation Type Inhibition

  Arsenic Trioxide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Arsenic Trioxide inhibits the expression of SLC28A3 [3]

  Zidovudine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Zidovudine increases the expression of SLC28A3 [4]

  Zoledronic Acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Zoledronic Acid increases the expression of SLC28A3 [5]

  Uridine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Uridine inhibits the activity of SLC28A3 [1]

Drug in Phase 3 Trial

  Triclosan

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Triclosan inhibits the expression of SLC28A3 [9]

  Sulforafan

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Sulforafan inhibits the expression of SLC28A3 [11]

  Inosine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Inosine inhibits the activity of SLC28A3 [13]

Drug in Preclinical Test

  (+)-JQ1

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 (+)-JQ1 inhibits the expression of SLC28A3 [8]

Discontinued Drug

  Tecadenoson

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tecadenoson inhibits the transportation of Uridine by SLC28A3 [1]

Affected Drug/Substrate

 Uridine Modulation Type Inhibition

Investigative Drug

  Phloretin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Phloretin inhibits the transportation of Uridine by SLC28A3 [2]

Affected Drug/Substrate

 Uridine Modulation Type Inhibition

  Phlorizin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Phlorizin inhibits the transportation of Uridine by SLC28A3 [2]

Affected Drug/Substrate

 Uridine Modulation Type Inhibition

  Milchsaure

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Milchsaure inhibits the expression of SLC28A3 [10]

Natural Product

  Cholesterol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cholesterol increases the expression of SLC28A3 [7]

  Tobacco Smoke Pollution

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tobacco Smoke Pollution inhibits the expression of SLC28A3 [12]

Carcinogen

  Benzo(a)pyrene

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Benzo(a)pyrene inhibits the expression of SLC28A3 [6]
References
1 Transport of A1 adenosine receptor agonist tecadenoson by human and mouse nucleoside transporters: evidence for blood-brain barrier transport by murine equilibrative nucleoside transporter 1 mENT1. Drug Metab Dispos. 2013 Apr;41(4):916-22.
2 Synthesis and biological evaluation of phloridzin analogs as human concentrative nucleoside transporter 3 (hCNT3) inhibitors. Bioorg Med Chem Lett. 2009 Feb 1;19(3):917-21.
3 Global effects of inorganic arsenic on gene expression profile in human macrophages. Mol Immunol. 2009 Feb;46(4):649-56.
4 Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23.
5 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
6 Transcriptional signature of human macrophages exposed to the environmental contaminant benzo(a)pyrene. Toxicol Sci. 2010 Apr;114(2):247-59.
7 Human Mincle Binds to Cholesterol Crystals and Triggers Innate Immune Responses. J Biol Chem. 2015 Oct 16;290(42):25322-32.
8 CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest. 2016 Feb;126(2):639-52.
9 Transcriptome and DNA Methylome Dynamics during Triclosan-Induced Cardiomyocyte Differentiation Toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
10 Transcriptional profiling of lactic acid treated reconstructed human epidermis reveals pathways underlying stinging and itch. Toxicol In Vitro. 2019 Jun;57:164-173.
11 Transcriptome and DNA methylation changes modulated by sulforaphane induce cell cycle arrest, apoptosis, DNA damage, and suppression of proliferation in human liver cancer cells. Food Chem Toxicol. 2020 Feb;136:111047.
12 Integration of transcriptome analysis with pathophysiological endpoints to evaluate cigarette smoke toxicity in an in vitro human airway tissue model. Arch Toxicol. 2021 May;95(5):1739-1761.
13 Cyclic ADP-ribose mediates formyl methionyl leucyl phenylalanine (fMLP)-induced intracellular Ca(2+) rise and migration of human neutrophils. J Pharmacol Sci. 2008 Mar;106(3):492-504.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.